ZEVRA THERAPEUTICS, INC.

By person

22 insiders · 175 transactions

5.9×

Neil F. McFarlane holds 5.9 times base salary in stock. $4.31M of shares against $729.17K in salary for 2025.

Salary from the company's own proxy. The shares are what Neil F. McFarlane last reported holding, valued at $11.13, the price Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Delaware Street Capital Master Fund, L.P. entity

10% owner

$8.28M (5)

—

+$8.28M

4,095,914

6.90%

$45.58M

+179.4%

McFarlane Neil F.

President and CEO

—

$1.92M (5) scheduled

−$1.92M

387,225

0.6521%

$4.31M

+674.5%

Thompson Rahsaan

Chief Legal & Compliance

—

$1.19M (5) scheduled

−$1.19M

37,569

0.0633%

$418.06K

—

Bode John B

Director

$285.86K (10)

—

+$285.86K

123,400

0.2078%

$1.37M

—

Mickle Travis C

President & CEO

$258.80K (24)

—

+$258.80K

752,182

1.27%

$8.37M

+39.3%

Schafer Joshua

CCO

$17.20K (3)

$208.83K (3) scheduled

−$191.63K

62,278

0.1049%

$693.01K

+5,301%

Shih Alvin

Director

$157.80K (1)

—

+$157.80K

20,000

0.0337%

$222.55K

—

Pascoe Richard W

Chief Executive Officer

$136.44K (13)

—

+$136.44K

29,973

0.0505%

$333.53K

—

Cohen Daniel L

EVP, Govt. & Public Relations

$131.18K (15)

—

+$131.18K

3,450

0.0058%

$38.39K

—

Watton Corey Michael

Director

$11.78K (5)

$138.38K (1) scheduled

−$126.60K

1,800

0.0030%

$20.03K

—

Anderson Thomas

Director

$116.83K (2)

—

+$116.83K

20,000

0.0337%

$222.55K

—

Braun Samuel J

10% owner

$85.50K (1)

—

+$85.50K

3,070,000

5.17%

$34.16M

+0.3%

Plooster Matthew R

Director

$70.93K (5)

—

+$70.93K

19,617

0.0330%

$218.29K

—

Tierney David S

Director

$55.82K (8)

—

+$55.82K

10,835

0.0182%

$120.57K

—

Sangiovanni Timothy J.

SVP, Finance & Corp Controller

$17.60K (9)

$66.58K (3) scheduled

−$48.98K

29,590

0.0498%

$329.27K

—

Quartel Adrian W

Chief Medical Officer

—

$40.04K (1) scheduled

−$40.04K

9,723

0.0164%

$108.19K

+232.6%

Johnson Gordon K

Chief Business Officer

$36.81K (11)

—

+$36.81K

40,000

0.0674%

$445.11K

+1,900%

FAVORITO TAMARA A

Director

$28.19K (3)

—

+$28.19K

3,894

0.0066%

$43.33K

—

Clifton R. LaDuane

Former CFO & Treasurer

$105.16K (37)

$86.47K (1) scheduled

+$18.69K

143,515

0.2417%

$1.60M

—

Mickle Christal M M

Chief Development Officer

$8.20K (1)

—

+$8.20K

2,353,531

3.96%

$26.19M

+0.1%

Thompson Danny L

Director

—

190,747

0.3212%

$2.12M

+10.7%

Saluri Joseph

Director

—

20,899

0.0352%

$232.56K

+358.8%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Thompson Rahsaan

14 Aug 2026

Chief Legal & Compliance

Sold on a plan

42,666

$11.13

$474.77K

Thompson Rahsaan

22 Jun 2026

Chief Legal & Compliance

Sold on a plan

34,557

$12.68

$438.30K

Thompson Rahsaan

11 May 2026

Chief Legal & Compliance

Sold on a plan

1,794

$11.30

$20.27K

McFarlane Neil F.

9 Feb 2026

President and CEO

Sold on a plan

14,625

$8.56

$125.19K

Schafer Joshua

3 Feb 2026

CCO

Sold on a plan

10,500

$9.19

$96.50K

Sangiovanni Timothy J.

3 Feb 2026

SVP, Finance & Corp Controller

Sold on a plan

3,000

$9.18

$27.55K

McFarlane Neil F.

2 Feb 2026

President and CEO

Sold on a plan

91,000

$9.38

$853.43K

Thompson Rahsaan

26 Jun 2025

Chief Legal & Compliance

Sold on a plan

24,000

$9.21

$221.00K

McFarlane Neil F.

14 Feb 2025

President and CEO

Sold on a plan

30,544

$8.05

$245.96K

McFarlane Neil F.

13 Feb 2025

President and CEO

Sold on a plan

61,273

$7.86

$481.43K

Clifton R. LaDuane

13 Feb 2025

CFO & Treasurer

Sold on a plan

11,000

$7.86

$86.47K

Schafer Joshua

13 Feb 2025

CCO & EVP, Bus. Development

Sold on a plan

10,500

$7.86

$82.53K

Sangiovanni Timothy J.

13 Feb 2025

SVP, Finance & Corp Controller

Sold on a plan

3,000

$7.86

$23.59K

Show all 175 transactions →

ZEVRA THERAPEUTICS, INC.

By person

Individual transactions

What was left out